Latest News
Coupang Shares Plunge 16% on $266M Q1 Loss from Cyberattack Fallout
Coupang posted a $266M net loss in Q1, citing costs from a data breach. Shares fell 16.6%. Revenue grew 8% to $8.5B, but operating loss widened to $242M.
Cencora Shares Drop 13% on Revenue Outlook Cut Despite Profit Upgrade
Cencora shares tumbled 13.5% after the company slashed its full-year revenue growth forecast, missing quarterly estimates, even as it raised its profit outlook and unveiled a $1 billion buyback.
SolarEdge Shares Tumble as Wider Loss Clouds Revenue Growth
SolarEdge shares dropped 6% after a Q1 adjusted loss exceeded expectations, even as revenue grew 46% to $310.5 million. The company's turnaround faces headwinds from U.S. demand softness and competitive pressure.
Avalo Therapeutics Soars 34% on $375M Offering Following Positive Phase 2 HS Data
Avalo Therapeutics shares surged 34% after pricing a $375M public offering, following positive Phase 2 results for abdakibart in hidradenitis suppurativa. The company aims to fund Phase 3 development.
Klaviyo Shares Crash 30% as CFO Departure Overshadows Strong Q1 Results
Klaviyo shares fell 30% Wednesday as CFO Amanda Whalen's planned exit overshadowed a Q1 earnings beat and raised 2026 outlook.
TransMedics Shares Slide 23% on Earnings Miss, Despite Revenue Growth
TransMedics shares plunged 23% after Q1 adjusted earnings of $0.30 missed estimates, despite a 21% revenue increase. Profit fell sharply as costs rose.
Qualcomm Stock Surges Past $200 on AI Data Center Push and Hyperscaler Deal
Qualcomm shares rose 1.8% to $189.83 after hitting $200.34, driven by AI data center chip demand and a custom silicon deal with a top cloud operator.
Oscar Health Shares Surge 5% as Q1 Profit Doubles, 2026 Forecast Maintained
Oscar Health reported Q1 net income of $679M, more than double last year, with revenue up 53% to $4.65B. Shares rose 5.3% as the company reaffirmed its 2026 guidance.
POET Technologies Faces Class Action After Marvell Cancels Celestial AI Orders
POET Technologies is under a securities class action after Marvell canceled all Celestial AI purchase orders. Lead-plaintiff deadline is June 29. Stock at $9.385.
Palantir Drops Despite Record Revenue; Commercial Miss Triggers Selloff
Palantir shares slipped 1.4% to $134.04 despite record quarterly revenue of $1.63B. A $10M miss in U.S. commercial revenue triggered the decline, even as the company raised 2026 guidance.
